中国卫生标准管理
中國衛生標準管理
중국위생표준관리
China Health Standard Management
2015年
28期
114-115
,共2页
李翔%李漫丽%崔红培%武文忠%范珂
李翔%李漫麗%崔紅培%武文忠%範珂
리상%리만려%최홍배%무문충%범가
雷珠单抗%黄斑水肿%黄斑格栅样光凝
雷珠單抗%黃斑水腫%黃斑格柵樣光凝
뢰주단항%황반수종%황반격책양광응
Ranibizumab%Diabetic macular edema%Macular grid photocoagulation
目的:探讨黄斑区格栅光凝(MGP)与玻璃体腔注射雷珠单抗(RZB)在治疗糖尿病黄斑水肿的作用。方法收集糖尿病黄斑水肿患者60例,随机分为A、B、C三组。对治疗前后最佳矫正视力(BCVA)和黄斑区视网膜厚度(CMT)进行分析。结果 B、C组在治疗后各时间点BCVA及CMT均好于A组,在术后8、12周C组的BCVA及CMT好于B组。结论 MGP联合RZB治疗更有利于视功能的改善,在RZB注射一周后再行MGP对治疗DME有更好的效果。
目的:探討黃斑區格柵光凝(MGP)與玻璃體腔註射雷珠單抗(RZB)在治療糖尿病黃斑水腫的作用。方法收集糖尿病黃斑水腫患者60例,隨機分為A、B、C三組。對治療前後最佳矯正視力(BCVA)和黃斑區視網膜厚度(CMT)進行分析。結果 B、C組在治療後各時間點BCVA及CMT均好于A組,在術後8、12週C組的BCVA及CMT好于B組。結論 MGP聯閤RZB治療更有利于視功能的改善,在RZB註射一週後再行MGP對治療DME有更好的效果。
목적:탐토황반구격책광응(MGP)여파리체강주사뢰주단항(RZB)재치료당뇨병황반수종적작용。방법수집당뇨병황반수종환자60례,수궤분위A、B、C삼조。대치료전후최가교정시력(BCVA)화황반구시망막후도(CMT)진행분석。결과 B、C조재치료후각시간점BCVA급CMT균호우A조,재술후8、12주C조적BCVA급CMT호우B조。결론 MGP연합RZB치료경유리우시공능적개선,재RZB주사일주후재행MGP대치료DME유경호적효과。
ObjectiveTo investigate the efficacy of ranibizumab(RZB)and macular grid photocoagulation(MGP)in the treatment of diabetic macular edema (DME). Methods60 cases with DME were randomly divided into three groups,the best corrected visual acuity(BCVA)and central macular thickness(CMT)were analyzed.ResultsAfter treatment,BCVA and CMT were improved more in group B and C than in group A,and they were better in group C than group B at 8,12 weeks after treatment.Conclusion RZB combined with MGP have more effect for DME treatment,later MGP have better effect.